|
|
Efficacy of Fuzheng Yiai Decoction Supplemented with Laparoscopic Radical Resection of Rectal Cancer in the Treatment of Early Rectal Cancer |
XIAO Gang, JIANG Jing, LUO Lu, et al |
The Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine, Shaanxi Xianyang 712000, China |
|
|
Abstract Objective: To explore the efficacy of Fuzheng Yiai decoction supplemented with laparoscopic radical resection of rectal cancer in the treatment of early rectal cancer. Methods: A total of 103 patients with early rectal cancer who underwent radical resection of rectal cancer in the hospital between February 2018 and September 2021 were selected as the research subjects, and they were divided into the treatment group and the control group according to the simple randomization method. The control group (n=51) were given mosapride citrate tablets and FOLFOX4 chemotherapy after surgery, and the treatment group (n=52) was additionally treated with Fuzheng Yiai decoction on the basis of the control group. The scores of TCM syndromes, intestinal microecology, immune function, serum tumor markers [serum carcinoembryonic antigen (CEA), alpha-fetoprotein (AFP), Eotaxin-2, cyclooxygenase-2 (COX-2), carbohydrate antigen 199 (CA199)] and adverse drug reactions were compared between the two groups. Results: After 2 months of treatment, the scores of TCM syndromes in the two groups were significantly decreased (P<0.05), the densities of Escherichia coli and Enterococcus were significantly declined (P<0.05) while the densities of Lactobacillus and Bifidobacterium were significantly increased (P<0.05), the proportions of CD3+, CD4+ and NK cells in both groups were significantly enhanced (P<0.05) while the proportion of CD8+ cells was significantly reduced (P<0.05), and the levels of serum CEA, AFP, CA199, COX-2 and Eotaxin-2 were significantly lowered (P<0.05), and the improvement degrees of the above indicators in the treatment group were significantly higher than those in the control group (P<0.05). Conclusion: Laparoscopic radical resection supplemented with Fuzheng Yiai decoction for the treatment of patients with early rectal cancer has significant clinical efficacy and obvious improvements on intestinal microecology and body' immunity.
|
|
|
|
|
[1] 刘思达,刘栋,段降龙.腹腔镜辅助经肛门全直肠系膜切除术与全直肠系膜切除术的临床对比研究[J].中华普外科手术学杂志(电子版),2020,14(1):42-45. [2] 陈彬,梁芳,袁旭,等.健脾解毒方加减对脾气亏虚证晚期结直肠癌化疗患者肠道菌群及免疫功能的影响[J].中医杂志,2020,61(5):423-427. [3] 国家卫生计生委医政医管局;中华医学会肿瘤学分会.中国结直肠癌诊疗规范(2015版)[J].中华胃肠外科杂志,2015,(10):961-973. [4] 商洪才,王保和,张伯礼.中药新药证候及疗效评价[J].中药新药与临床药理,2004,(5):365-368. [5] 陈中建,苟菲,张天锋.复方斑蝥注射液辅助结直肠癌根治术治疗结直肠癌的效果及安全性分析[J].中华中医药学刊,2019,37(7):1718-1720. [6] 张晓双,陈希琦,李轩,等.补气活血化瘀药调控Th1/Th2通路干预结直肠癌术后的研究进展[J].中国中西医结合外科杂志,2021,27(2):355-357. [7] 刘首记,言纲,聂青.扶正抑瘤汤联合化疗对结直肠癌患者T淋巴细胞水平及转归的影响[J].世界中西医结合杂志,2021,16(6):1123-1127. [8] 余莉,李红,王思平.老年结直肠癌患者肠道菌群变化与机体免疫炎症营养相关性[J].中国微生态学杂志,2020,32(4):404-409,414. [9] 彭卓嵛,蔡林坤,蓝斯莹,等.COX-2和Cathepsin-D在结直肠癌组织中的表达及临床意义[J].中国肿瘤临床与康复,2020,27(2):152-155. [10] 徐小卫,董利阳,郑婷婷,等.嗜酸粒细胞趋化蛋白-2血清含量对结直肠癌的诊断价值[J].江苏大学学报(医学版),2022,32(1):54-57. |
[1] |
. [J]. HeBei Med, 2023, 29(7): 1226-1229. |
|
|
|
|